Literature DB >> 33822112

Cyclophosphamide-Free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women With Breast Cancer.

Matteo Lambertini1,2, Ann H Partridge3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33822112      PMCID： PMC8486328          DOI： 10.1093/jnci/djab066

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  24 in total

Review 1.  Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review.

Authors:  Jessica Howard-Anderson; Patricia A Ganz; Julienne E Bower; Annette L Stanton
Journal:  J Natl Cancer Inst       Date:  2012-01-23       Impact factor: 13.506

2.  Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.

Authors:  David Loesch; F Anthony Greco; Neil N Senzer; Howard A Burris; John D Hainsworth; Stephen Jones; Svetislava J Vukelja; John Sandbach; Frankie Holmes; Scot Sedlacek; John Pippen; Deborah Lindquist; Kristi McIntyre; Joanne L Blum; Manuel R Modiano; Kristi A Boehm; Feng Zhan; Lina Asmar; Nicholas Robert
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

3.  Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.

Authors:  Benedetta Conte; Marco Bruzzone; Matteo Lambertini; Francesca Poggio; Claudia Bighin; Eva Blondeaux; Michelino De Laurentiis; Enrichetta Valle; Francesco Cognetti; Cecilia Nisticò; Sabino De Placido; Ornella Garrone; Teresa Gamucci; Filippo Montemurro; Fabio Puglisi; Barbara Cardinali; Piero Fregatti; Loredana Miglietta; Francesco Boccardo; Marcello Ceppi; Lucia Del Mastro
Journal:  Eur J Cancer       Date:  2020-07-04       Impact factor: 9.162

4.  Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Rafael Caparica; Marco Bruzzone; Francesca Poggio; Marcello Ceppi; Evandro de Azambuja; Matteo Lambertini
Journal:  Breast Cancer Res Treat       Date:  2018-11-21       Impact factor: 4.872

5.  Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.

Authors:  Hyun-Ah Kim; Jong Won Lee; Seok Jin Nam; Byeong-Woo Park; Seock-Ah Im; Eun Sook Lee; Yong Sik Jung; Jung Han Yoon; Sung Soo Kang; Soo-Jung Lee; Kyong Hwa Park; Joon Jeong; Se-Heon Cho; Sung Yong Kim; Lee Su Kim; Byung-In Moon; Min Hyuk Lee; Tae Hyun Kim; Chanheun Park; Sung Hoo Jung; Geumhee Gwak; Jeryong Kim; Sun Hee Kang; Young Woo Jin; Hee Jeong Kim; Se-Hwan Han; Wonshik Han; Min Hee Hur; Woo Chul Noh
Journal:  J Clin Oncol       Date:  2019-09-16       Impact factor: 44.544

6.  Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.

Authors:  Lori J Goldstein; Anne O'Neill; Joseph A Sparano; Edith A Perez; Lawrence N Shulman; Silvana Martino; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2008-08-04       Impact factor: 44.544

7.  Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.

Authors:  Ann H Partridge; Kathryn J Ruddy; Shari Gelber; Lidia Schapira; Mary Abusief; Meghan Meyer; Elizabeth Ginsburg
Journal:  Fertil Steril       Date:  2009-05-05       Impact factor: 7.329

Review 8.  Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

Authors:  Harold J Burstein; Christina Lacchetti; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

9.  Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.

Authors:  Matteo Lambertini; Halle C F Moore; Robert C F Leonard; Sibylle Loibl; Pamela Munster; Marco Bruzzone; Luca Boni; Joseph M Unger; Richard A Anderson; Keyur Mehta; Susan Minton; Francesca Poggio; Kathy S Albain; Douglas J A Adamson; Bernd Gerber; Amy Cripps; Gianfilippo Bertelli; Sabine Seiler; Marcello Ceppi; Ann H Partridge; Lucia Del Mastro
Journal:  J Clin Oncol       Date:  2018-05-02       Impact factor: 44.544

10.  Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

Authors: 
Journal:  Lancet       Date:  2019-02-08       Impact factor: 79.321
View more
  1 in total

1.  Preventive Electroacupuncture Alleviates Oxidative Stress and Inflammation via Keap1/Nrf2/HO-1 Pathway in Rats with Cyclophosphamide-Induced Premature Ovarian Insufficiency.

Authors:  Yang Chen; Rui Zhao; Xiang Li; Yun-Peng Luan; Li-Wei Xing; Xiao-Juan Zhang; Jing Wang; Xiao-Yan Xia; Rong Zhao
Journal:  Biomed Res Int       Date:  2022-08-25       Impact factor: 3.246
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.